Form 4: Akero Therapeutics COO Jonathan Young Exercises Stock Options, Acquires Shares
SEC Form 4 Filing
Akero Therapeutics' Chief Operating Officer, Jonathan Young, exercised stock options and acquired 43,064 shares of common stock on January 24, 2025.
Summary
- Jonathan Young, the Chief Operating Officer of Akero Therapeutics, exercised stock options to acquire 43,064 shares of common stock on January 24, 2025.
- The exercise price for the options was $6.364 per share.
- Following the transaction, Mr. Young directly owns 261,147 shares of Akero Therapeutics common stock.
- Mr. Young also has indirect ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.
- These shares are held in three separate trusts, each holding 20,000 shares.
- Mr. Young disclaims beneficial ownership of the shares held in trust.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction, with no significant positive or negative implications. The exercise of options is a normal part of executive compensation.
Positives
- The exercise of stock options by a key executive like the COO can be seen as a positive sign of confidence in the company's future prospects.
Management Comments
- Jonathan Young disclaims beneficial ownership of the shares held in trust for his children.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives exercise stock options or trade company stock. It provides transparency into insider transactions.
Comparison to Industry Standards
- The filing is consistent with standard practices for reporting insider transactions in publicly traded companies.
- Similar filings are common across the biotechnology industry when executives exercise stock options.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it indicates executive confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 01/23/2025 | Date the stock options were exercisable. |
| 01/24/2025 | Date of the stock option exercise and share acquisition. |
| 01/27/2025 | Date the form was signed. |
| 01/15/2029 | Expiration date of the stock options. |
Keywords
stock options, insider trading, beneficial ownership, executive compensation, equity securities, Akero Therapeutics, AKRO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.